Passage BIO Inc
For the period ended Dec 31, 2024. Filed Mar 4, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 4, 2025
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| (in thousands, except share and per share data) · 2024 · 2023 | ||||||
| Assets · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $37,573 | | $21,709 | ||
| Marketable securities | | | 39,183 | | | 92,585 |
| Prepaid expenses and other current assets | | 838 | | 923 | ||
| Prepaid research and development | | 1,221 | | 2,742 | ||
| Total current assets | | 78,815 | | 117,959 | ||
| Property and equipment, net | | 9,331 | | 15,295 | ||
| Right of use assets - operating leases | | | 13,803 | | 16,858 | |
| Other assets | | 463 | | 433 | ||
| Total assets | | $102,412 | | $150,545 | ||
| Liabilities and stockholders’ equity | | | | |||
| Current liabilities: | | | | |||
| Accounts payable | | $742 | | $1,298 | ||
| Accrued expenses and other current liabilities | | 6,707 | | 11,670 | ||
| Non-refundable sublicense and transition services payments received | | | 8,226 | | | — |
| Operating lease liabilities | | | 3,688 | | 3,373 | |
| Total current liabilities | | 19,363 | | 16,341 | ||
| Operating lease liabilities - noncurrent | | 21,788 | | 22,921 | ||
| Total liabilities | | 41,151 | | 39,262 | ||
| | | | | | | |
| Commitments and contingencies (note 10) | | | | |||
| | | | | | | |
| Stockholders’ equity: | | | | |||
| Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both December 31, 2024 and December 31, 2023 | | | — | | | — |
| Common stock, $0.0001 par value: 300,000,000 shares authorized; 62,061,774 shares issued and outstanding at December 31, 2024 and 54,944,130 shares issued and outstanding at December 31, 2023 | | 6 | | 5 | ||
| Additional paid‑in capital | | 720,482 | | 705,789 | ||
| Accumulated other comprehensive income (loss) | | | 8 | | | (43) |
| Accumulated deficit | | (659,235) | | (594,468) | ||
| Total stockholders’ equity | | 61,261 | | 111,283 | ||
| Total liabilities and stockholders’ equity | | $102,412 | | $150,545 | ||
Passage Bio, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.